Synergistic improvement of rectal peptide combined with phenytoin on renal fibrosis

The combined use of the rectal peptide Proctolin and Macurin solves the problem of directly reversing renal fibrosis, significantly improves the degree of renal fibrosis, reduces structural damage, provides anti-fibrotic therapy with a multi-target synergistic mechanism, and reduces the risk of toxic side effects.

CN120501842BActive Publication Date: 2026-06-23JIANGNAN UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
JIANGNAN UNIV
Filing Date
2025-06-18
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

Currently, there are no specific drugs that can directly reverse renal fibrosis. Existing treatments mainly slow down the progression, and end-stage patients need to rely on renal replacement therapy, which places a heavy medical burden on healthcare.

Method used

The combined use of the rectal peptide Proctolin and pentoxydiphenyl ketone Macurin restores glomerular filtration function and inhibits the expression of fibrosis-related genes and proteins by downregulating the transcription of fibrosis markers Col1a1, Acta2, and Col3a1 and reducing extracellular deposition of fibrosis proteins, thus forming a synergistic inhibitory pathway.

Benefits of technology

It significantly improves the degree of renal fibrosis, reduces structural damage, lowers renal fibrosis-related serum creatinine and urea nitrogen levels, reduces inflammatory response and oxidative stress, provides anti-fibrotic effects through a multi-target synergistic mechanism, and reduces the risk of toxic side effects from high-dose single-drug therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120501842B_ABST
    Figure CN120501842B_ABST
Patent Text Reader

Abstract

The application discloses a synergistic improvement effect of rectal peptide and phohydroquinone on kidney fibrosis, and belongs to the technical field of biological medicine. The research results of the application show that Proctolin and Macurin can relieve kidney fibrosis by inhibiting the mRNA expression of fibrosis-related genes (Col1a1, Acta2, Col3a1) and Col3a1 protein deposition, and reducing the synthesis of extracellular matrix. In the TGF-beta induced cell model and the UUO animal model, Proctolin and Macurin both show a significant inhibitory effect on kidney fibrosis, and the combined use of the two has a more significant effect. In conclusion, Proctolin and Macurin can effectively improve the kidney fibrosis of mice, the in-vitro cell experiment is consistent with the in-vivo animal model results, and the mixed drug has a better effect, which provides an experimental basis for developing an anti-fibrosis compound drug.
Need to check novelty before this filing date? Find Prior Art